Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS AssetsPR Newswire • 5 days ago
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets Harmony Biosciences Acquires Epygenix Therapeutics, Inc...
Share to Feed
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 PR Newswire PLYMOUTH MEETING...
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT...
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL...
Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight research firms that are presently covering the...
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE PR Newswire PLYMOUTH...
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY Get Free Report) insider Jeffrey Dierks sold 11,979 shares of the firms stock in a transaction dated Friday, March 15th. The shares were...
Related Stocks: HRMY...
Exchange Traded Concepts LLC grew its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY Free Report) by 0.8% during the fourth quarter, according to the company in its most recent...
HRMY's total volume now sits at 1.2M. The +1.95% price change was insignificant, leaving IBM's price at $31.97...